| Establishing Specific Response Criteria for MDS/MPN - Getting Closer to Reality? |
|
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
| SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype - A Proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM) |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Rewriting the rules for care of MDS and AML patients in the time of COVID-19 |
|
Leukemia Research Reports |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Alcohol use is not a significant contributor to myelodysplastic syndromes |
|
Cancer Causes & Control : CCC |
Myelodysplastic Syndromes (MDS) |
| Targeting TP53 Mutations in Myelodysplastic Syndromes |
|
Hematology/oncology clinics of North America |
Myelodysplastic Syndromes (MDS) |
| Evolving therapies for lower-risk myelodysplastic syndromes |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities |
|
Clinical Lymphoma , Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
| Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter? |
|
Expert Review of Hematology |
Myelodysplastic Syndromes (MDS) |
| Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment |
|
European Journal of Haematology |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
| Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes |
|
The New England Journal of Medicine |
Myelodysplastic Syndromes (MDS) |
